Skip to main content

Table 3 Safety of ulinastatin in clinical practice

From: Real-world safety of ulinastatin: a post-marketing surveillance of 11,252 patients in China

Adverse drug reaction

ICU

General ward

patients (n)

events (n)

patients (n)

events (n)

Possibly related

 Abnormal liver function

3

3 *

1

1

 Liver function damage

1

1

0

0

 Thrombocytosis

1

1

1

1

 Thrombocytopenia

1

1

0

0

 Leukocytosis

1

1

0

0

 Rash

1

1

0

0

Probably related

 Leukopenia

1

1

0

0

Sum

9

9

2

2

  1. * 1 patient occurred grade 4 ADR/ADE of abnormal liver function, and the other 10 patients were all grade 1 or 2